Fig. 7: Memory T cell and antibody responses are differentially dependent on the prime-boost interval in Trial US. | npj Vaccines

Fig. 7: Memory T cell and antibody responses are differentially dependent on the prime-boost interval in Trial US.

From: Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials

Fig. 7

Log10 transformed EC90 titers (a–c) or percent of memory T cells responding to stimulation with any tested cytokine production (d, e) of samples from US participants (y axis) are plotted against the interval in weeks between the participant’s cAd3-Ebola prime and MVA-EbolaZ boost vaccinations (x axis). Spearman correlations p, and rho are included for each comparison. A simple linear regression line and its slope is included for reference. For antibody titers, correlations were performed comparing the prime-boost interval against week four (a), 24, (b) and 48 (c) EBOZ GP-specific antibody titers after the boost, whereas for T cells the comparison used CD4 (d) and CD8 (e) T cell percentages from week 4 only.

Back to article page